Center for Translational Cancer Nanomedicine
The main objective of the Center for Translational Cancer Nanomedicine is to develop, test pre-clinically in vitro and in vivo, characterize, scale up, and manufacture under Good Manufacturing Practice (GMP) conditions test batches of the most promising nanopreparations for cancer, with a particular focus on lung, ovarian, and pancreatic cancer. Nanocarriers will include polymeric micelles, liposomes, polymeric particles, and dendrimers, while the drugs to be used will include pro-apoptotic agents, DNA, and siRNA together with diagnostic labels.
Vladimir Torchilin, Ph.D., D.Sc.
Nahum Goldberg, M.D.
- Project 1: Combined Targeted Micellar Preparations of Novel Proapoptotic Drug and siRNA for Cancer
- Project 2: Combined Cancer Therapy with RF Ablation and Drug-Loaded Nanopreparations
- Project 3: Multi-Modal Gene Therapy for Pancreatic Cancer Using Targeted Nanovectors
- Project 4: Development and High-Throughput Screening of Targeted Anti-Cancer Nanomedicines
- Core A: Physico-Chemical Nanocharacterization Core
- Core B: Imaging Core
- Core C: Scaling Up and Manufacturing Core